C14H14N2O2S, triclinic, P1̄, a = 8.6471(4) Å, b = 9.5576(5) Å, c = 9.7098(5) Å, α = 91.054(2)°, β = 109.380(2)°, γ = 113.769(2)°, V = 681.95(6) Å3, Z = 2, Rgt(F) = 0.061, wRref(F2) = 0.175, T = 296(2)
C16H13NO2S, P1̅ (no. 2), a = 8.0873(4) Å, b = 12.7820(7) Å, c = 13.5574(7) Å, α = 74.880(2)°, β = 75...
C14H11N3S2, triclinic, P1̅ (no. 2), a = 5.7607(5)Å, b = 9.8397(9) Å, c = 12.0920(11) Å, α = 72.899(4...
C38H58N10O6S4, monoclinic, P21 (no. 4), a = 11.9542(5) Å, b = 11.4057(5) Å, c = 17.2763(8) Å, β = 96...
C13H14N2O2S, triclinic, P1̅ (no. 2), a = 4.8885(2) Å, b = 10.3414(5) Å, c = 12.6056(6) Å, α = 95...
C8H13N3S2, triclinic, P1̅ (no. 2), a = 7.4803(3) Å, b = 8.4562(3) Å, c = 9.3531(3) Å, α = 67.688(1)°...
C34H54N10O6S6, monoclinic, P21 (no. 4), a = 11.8434(5) Å, b = 11.2298(6) Å, c = 17.0706(8) Å, β = 94...
[C21H28N4S2], monoclinic, P21/c (no. 14), a = 16.1880(2) Å, b = 6.8168(1) Å, c = 19.7605(2) Å, β = 1...
The title compound, C9H8N2O2S3, crystallizes with two mol-ecules (A and B) in the asymmetric unit. B...
C11H11NO3S, triclinic, P (1) over bar (No. 2), a = 7.240(1) Angstrom, b = 7.495(2)Angstrom, c = 10.4...
C15H18N2O4S2, monoclinic, P121/c1 (No. 14), a = 8.754(3) Å, b = 12.499(2) Å, c = 15.599(3) Å, β = 95...
C26H18N6ZnS4, triclinic, P1‾$P‾{1}$ (no. 2), a = 9.4677(13) Å, b = 12.0147(17) Å, c = 13.571(...
C11H14N2O3S, orthorhombic, Pbca (no. 61), a = 10.1973(3) Å, b = 9.9487(4) Å, c = 23.1332(8) Å, V ...
C20H23N3O5S, monoclinic, P21/c (no. 14), a = 6.7503(2) Å, b = 14.0026(7) Å, c = 21.954(1) Å, β =...
In the title compounds, C11H13N3O2S, (I), and C16H15N3O2S, (II), the thiosemicarbazone group adopts ...
C15H18N2O4S2, monoclinic, P12/c1 (No. 14), a = 8.754(3) \uc5, b = 12.499(2) \uc5, c = 15.599(3) \uc5...
C16H13NO2S, P1̅ (no. 2), a = 8.0873(4) Å, b = 12.7820(7) Å, c = 13.5574(7) Å, α = 74.880(2)°, β = 75...
C14H11N3S2, triclinic, P1̅ (no. 2), a = 5.7607(5)Å, b = 9.8397(9) Å, c = 12.0920(11) Å, α = 72.899(4...
C38H58N10O6S4, monoclinic, P21 (no. 4), a = 11.9542(5) Å, b = 11.4057(5) Å, c = 17.2763(8) Å, β = 96...
C13H14N2O2S, triclinic, P1̅ (no. 2), a = 4.8885(2) Å, b = 10.3414(5) Å, c = 12.6056(6) Å, α = 95...
C8H13N3S2, triclinic, P1̅ (no. 2), a = 7.4803(3) Å, b = 8.4562(3) Å, c = 9.3531(3) Å, α = 67.688(1)°...
C34H54N10O6S6, monoclinic, P21 (no. 4), a = 11.8434(5) Å, b = 11.2298(6) Å, c = 17.0706(8) Å, β = 94...
[C21H28N4S2], monoclinic, P21/c (no. 14), a = 16.1880(2) Å, b = 6.8168(1) Å, c = 19.7605(2) Å, β = 1...
The title compound, C9H8N2O2S3, crystallizes with two mol-ecules (A and B) in the asymmetric unit. B...
C11H11NO3S, triclinic, P (1) over bar (No. 2), a = 7.240(1) Angstrom, b = 7.495(2)Angstrom, c = 10.4...
C15H18N2O4S2, monoclinic, P121/c1 (No. 14), a = 8.754(3) Å, b = 12.499(2) Å, c = 15.599(3) Å, β = 95...
C26H18N6ZnS4, triclinic, P1‾$P‾{1}$ (no. 2), a = 9.4677(13) Å, b = 12.0147(17) Å, c = 13.571(...
C11H14N2O3S, orthorhombic, Pbca (no. 61), a = 10.1973(3) Å, b = 9.9487(4) Å, c = 23.1332(8) Å, V ...
C20H23N3O5S, monoclinic, P21/c (no. 14), a = 6.7503(2) Å, b = 14.0026(7) Å, c = 21.954(1) Å, β =...
In the title compounds, C11H13N3O2S, (I), and C16H15N3O2S, (II), the thiosemicarbazone group adopts ...
C15H18N2O4S2, monoclinic, P12/c1 (No. 14), a = 8.754(3) \uc5, b = 12.499(2) \uc5, c = 15.599(3) \uc5...
C16H13NO2S, P1̅ (no. 2), a = 8.0873(4) Å, b = 12.7820(7) Å, c = 13.5574(7) Å, α = 74.880(2)°, β = 75...
C14H11N3S2, triclinic, P1̅ (no. 2), a = 5.7607(5)Å, b = 9.8397(9) Å, c = 12.0920(11) Å, α = 72.899(4...
C38H58N10O6S4, monoclinic, P21 (no. 4), a = 11.9542(5) Å, b = 11.4057(5) Å, c = 17.2763(8) Å, β = 96...